This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
The management of depression during pregnancy is complicated by the risks to the mother and the fetus by both the disease state itself as well as the medications used to treat it. Serotonin reuptake inhibitors, which include the selective serotonin reuptake inhibitors (SSRIs), are commonly used medications for the treatment of depression and other mood disorders. SSRIs readily cross the placenta and can affect fetal 5-hydroxytryptamine levels. Research into the effects of SSRIs on neonates has shown conflicting results, likely confounded by the fact that maternal depression itself may also lead to adverse outcomes for the neonate. This review aims to discuss the link between markers of fetal central nervous damage and maternal SSRI use, evaluate the literature reporting various short- and long-term neurologic effects in neonates after maternal use of SSRIs, and develop recommendations for the management of and parental counseling about various adverse neurologic outcomes of SSRI use during pregnancy.
- Copyright © 2016 by the American Academy of Pediatrics
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
Pay Per Article - You may access this article (from the computer you are currently using) for 2 days for US$25.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.